<DOC>
	<DOCNO>NCT02588781</DOCNO>
	<brief_summary>Pemetrexed anticancer agent exert action disrupt crucial folate-dependent metabolic process essential cell replication . In vitro study show pemetrexed behaves multitargeted antifolate inhibiting thymidylate synthase ( TS ) , dihydrofolate reductase ( DHFR ) , glycinamide ribonucleotide formyltransferase ( GARFT ) , key folate-dependent enzyme de novo biosynthesis thymidine purine nucleotides.Pemetrexed used standard therapeutic agent lung cancer , pleural mesothelioma , peritoneal mesothelioma.In addition effective anti-cancer effect , Pemetrexed severe side effect medicine . Pemetrexed research colon cancer . Zhang , etc. , demonstrate anti-cancer effect Pemetrexed human colon cancer Cells . Although sometimes make also two clinical study , Pemetrexed report 15-17 % treatment response rate two study .</brief_summary>
	<brief_title>Pemetrexed Alone Salvage Treatment Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy : A Phase II Single Arm Prospective Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Subject least 20 year age . 2 . Written voluntary inform consent understood , sign date . 3 . They must refractory progressive colorectal cancer curative therapy available . 4 . Subject able adhere study visit schedule protocol requirement . 5 . ECOG 02 6 . At least one measurable lesion accurately assess image physical examination baseline follow visit . 7 . Must life expectancy 3 month 8 . Demonstrate adequate organ function 9 . Negative urine serum pregnancy test within 28 day study treatment 10 . Be willing provide fresh tissue biomarker analysis , , base adequacy tissue sample quality assessment biomarker status . 1 . ECOG â‰¥ 3 2 . History malignancy last 5 year . 3 . Subject known historical active infection HIV , hepatitis B , hepatitis C. 4 . Breastfeeding pregnant female 5 . Patients administration Folic acid Vitamin B12 . 6 . Before treatment Pemetrexed . 7 . Patients swallow oral medication . 8 . The recent treatment clinical trial drug 14 day prior enrollment . 9 . Systemic chemotherapy within three week administration last test treatment , radiation therapy patient administer . 10 . Except hair loss , induced cancer treatment , toxicity progress ( &gt; CTCAE1 grade ) . 11 . Upper GI bleed within registration 4 week Bowel obstruction CTCAE3 4 grade . 12 . Subject experience recent myocardial infarction , include severe/unstable angina pectoris , coronary/peripheral artery bypass graft , uncontrolled hypertension , clinically significant cardiac dysrhythmia clinically significant electrocardiogram ( ECG ) abnormality , significant uncontrolled cardiovascular disease CHF , cerebrovascular accident transient ischemic attack , seizure disorder past year .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>